Company / Operating Income
Vanda Pharmaceuticals Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$14.0M
FY2025
5-year range
-$14.0M / $42.2M
FY2021-FY2025
Trend
-320.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income changed -320% YoY in FY2025, a notable deviation from the 9-year average annual change of -37%.
Based on SEC 10-K filings.
-$14M in FY2025.
Declined from $42M to -$14M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 320.4% year-over-year.
- Peak operating income was recorded in FY2023.
- Lowest operating income in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$14.0M | -320.4% |
| FY2024 | $6.3M | -85.0% |
| FY2023 | $42.2M | +54.8% |
| FY2022 | $27.2M | +19.4% |
| FY2021 | $22.8M | +4.9% |
| FY2020 | $21.7M | +228.6% |
| FY2019 | -$16.9M | +9.0% |
| FY2018 | -$18.6M | +53.8% |
| FY2017 | -$40.2M | -300.3% |
| FY2016 | $20.1M | +194.6% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026